Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a glowing dye reveal hidden bladder cancer during surgery?

NCT ID NCT07800507

Diagnosis Sponsor: Yunnan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether a fluorescent dye called TTP-ICG, which targets a protein found on bladder cancer cells, can help surgeons spot tumors during surgery. People with suspected or confirmed non-muscle invasive bladder cancer will have the dye placed into their bladder before surgery. A special camera that sees both white light and near-infrared fluorescence will then be used to guide removal of suspicious tissue. The study will check how safe the dye is and how accurately it identifies cancer compared to standard white-light imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TTP-ICG, a fluorescent dye that targets a protein on bladder cancer cells
What this could lead to
If it works, this could make bladder cancer surgery more precise, reducing the chance of leaving cancer behind and lowering the need for repeat procedures.
What could go wrong
This is an early-phase trial with only 30 participants, so the dye's accuracy and safety are not yet proven. It may not improve detection enough to change surgical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 80 years old * Patients with suspected or confirmed bladder tumor who are scheduled for transurethral partial bladder resection * Capable of providing written informed consent and adhering to the study protocol Exclusion Criteria: * Diagnosis of other invasive malignant tumors * Severe comorbidities, including congenital malformations, acute inflammatory disease, cachexia, myocardial infarction or cerebrovascular stroke within the previous 6 months, severe liver or renal insufficiency * Pregnant or breastfeeding female patients * Patients with gross hematuria or a history of allergic reactions to drugs or food * Concurrent cystitis, urinary tract malformation or urethral stricture * Enrollment in another interventional clinical trial within 30 days prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMIBC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMIBC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yunnan Cancer Hospital

    Kunming, Yunnan, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.